Dr. Bodepudi Haribabu to Lead Sequent Scientific as MD & CEO After Merger
Hyderabad: Pharmaceutical firm Sequent Scientific Limited has successfully completed a major corporate restructuring, formalising its amalgamation with Viyash Life Sciences, the company announced. The merger, which took effect on December 16, 2025, is accompanied by a significant leadership overhaul, highlighted by the appointment of industry veteran Dr. Haribabu Bodepudi as the new Managing Director and Group CEO.
The move marks a transformative phase for the company, underpinned by a substantial expansion of its capital base. Following the board's approval on Tuesday, Sequent Scientific has increased its paid-up equity share capital from ₹50.82 crore to ₹87.21 crore. The company’s authorised share capital has also been raised to ₹886.15 crore, positioning it for future growth.
This financial restructuring was facilitated by the allotment of 18.19 crore equity shares and 2.03 crore warrants to the shareholders of Viyash Life Sciences, based on a record date of December 8, 2025. The amalgamation also establishes CA Hull Investments as the new promoter of the consolidated entity.
Leading the newly integrated company is Dr. Bodepudi Haribabu, who brings extensive global pharmaceutical experience, notably from his previous role as the Global Chief Operating Officer at Mylan Laboratories. He has been appointed for a two-year term.
The new leadership structure also includes several key appointments. Rajaram Narayanan will continue in his role as CEO of the Animal Health division, while Srinivas Vasireddy has been named a Whole-time Director. The company further announced that Ramakant Singani is set to take over as the new Chief Financial Officer, effective January 1, 2026.
These strategic decisions, ratified at the board meeting on December 16, signal a comprehensive overhaul of Sequent Scientific's operational and financial framework as it embarks on its next chapter of growth.
The move marks a transformative phase for the company, underpinned by a substantial expansion of its capital base. Following the board's approval on Tuesday, Sequent Scientific has increased its paid-up equity share capital from ₹50.82 crore to ₹87.21 crore. The company’s authorised share capital has also been raised to ₹886.15 crore, positioning it for future growth.
This financial restructuring was facilitated by the allotment of 18.19 crore equity shares and 2.03 crore warrants to the shareholders of Viyash Life Sciences, based on a record date of December 8, 2025. The amalgamation also establishes CA Hull Investments as the new promoter of the consolidated entity.
Leading the newly integrated company is Dr. Bodepudi Haribabu, who brings extensive global pharmaceutical experience, notably from his previous role as the Global Chief Operating Officer at Mylan Laboratories. He has been appointed for a two-year term.
The new leadership structure also includes several key appointments. Rajaram Narayanan will continue in his role as CEO of the Animal Health division, while Srinivas Vasireddy has been named a Whole-time Director. The company further announced that Ramakant Singani is set to take over as the new Chief Financial Officer, effective January 1, 2026.
These strategic decisions, ratified at the board meeting on December 16, signal a comprehensive overhaul of Sequent Scientific's operational and financial framework as it embarks on its next chapter of growth.